RDY

Dr. Reddy’s Laboratories Ltd ADR
NYSEHEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC

Key Statistics

Market Cap
$12.39B
P/E Ratio
41.28
EPS
$0.36
Beta
0.20
52W High
$15.49
52W Low
$11.28
50-Day MA
$12.88
200-Day MA
$13.26
Dividend Yield
0.56%
Profit Margin
8.49%
Forward P/E
32.36
PEG Ratio
2.06

About Dr. Reddy’s Laboratories Ltd ADR

Dr. Reddy's Laboratories Limited is a globally integrated pharmaceutical company. The company is headquartered in Hyderabad, India.

Official WebsiteUSAFY End: March

Fundamentals

Revenue (TTM)$329.84B
Gross Profit (TTM)$163.24B
EBITDA$49.79B
Operating Margin14.70%
Return on Equity7.34%
Return on Assets3.37%
Revenue/Share (TTM)$66.15
Book Value$0.82
Price-to-Book3.06
Price-to-Sales (TTM)0.04
EV/Revenue3.489
EV/EBITDA18.82
Quarterly Earnings Growth (YoY)-35.70%
Quarterly Revenue Growth (YoY)-1.50%
Shares Outstanding$833.66M
Float$3.59B
% Insiders0.00%
% Institutions14.71%

Historical Volatility

HV 10-Day
24.72%
HV 20-Day
23.65%
HV 30-Day
25.02%
HV 60-Day
24.04%
HV Rank
44.8%

Volatility is currently contracting

Analyst Ratings

Consensus ($14.50 target)
2
Buy
2
Hold
1
Sell

Latest News

Dr. Reddy's Laboratories Q2 Earnings Call Highlights

Dr. Reddy's Laboratories NYSE: RDY reported second-quarter FY2027 revenue of INR 8,671 crore, or $905 million, down 1.5% from a year earlier but up 7.4% sequentially, as lower North American lenalidomide sales offset growth in its underlying business.

MarketBeat10/23/2026Neutral

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on RDY and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

Data last updated: 11/12/2026